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Introduction
Posthypoxic myoclonus (PHM) is a rare but severe and disabling condi-
tion, affecting a relatively young population.1 First reported in 1939, it was 
described more systematically only in 1963 when Lance and Adams 
reported four patients who developed intention and action myoclonus 
after sudden hypoxic encephalopathy.2 Since then, Lance–Adams syn-
drome (LAS), or chronic PHM, has been recognized as a well-defined 
clinical syndrome, where ataxia, dysarthria, and gait abnormalities are 
variably associated with intention, action, and/or stimulus-induced myoc-
lonus.3 Usually, these neurologic symptoms improve slowly over time after 
the initial insult, while myoclonus may persist, frequently severely affect-
ing the quality of  life of  patients who have otherwise recovered.1 
Classically, symptoms start within days or weeks after the causal event, 
usually a cardiopulmonary arrest. LAS can present as generalized or mul-
tifocal myoclonus, mainly affecting the limbs and interfering with fine 
motor skills. Negative myoclonus of  the legs may be present, causing 
inability to stand and a classic bouncing appearance when patients try 
to ambulate.
Myoclonus in PHM can be cortical or subcortical (reticular reflex 
myoclonus), and a combination of  the two is often present in the same 
patient.4 Although the pathophysiologic understanding of  PHM is 
 incomplete, the serotoninergic and the gamma-aminobutyric acid-ergic 
(GABAergic) systems seem to play a central role.5,6 Imaging and neuro-
physiological studies have been performed in order to characterize the 
drivers of  PHM.7,8,9,10,11 Combined neurophysiological recording con-
firmed abnormal electrical activities usually with a cortical origin, mostly 
in the sensory motor area.12 The electrical activity of  electroencephalo-
gram (EEG) and electromyography (EMG) recordings is usually inconsis-
tently time-locked, and epileptic features such as polyspike and spike-wave 
activity are present in the majority of  cases.13 However, imaging studies 
are suggestive of  not only a cortical involvement that has been mainly 
reported in the frontal lobe, but also of  the parietal and temporal lobes, 
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consistently with the involvement of  the sensory motor area. Indeed, 
metabolic abnormalities and restricted diffusion were reported also in 
the cerebellum, thalamus, lenticular, and pontine nuclei.12 Thus, it is 
possible that an impaired connectivity from subcortical areas is respon-
sible for the abnormal cortical discharge that generates the myoclonus.
The treatment of  PHM can be very challenging, limited by a paucity 
of  class I trials and the rarity of  the condition. According to the litera-
ture, clonazepam, valproic acid, and levetiracetam are the most effective 
treatments, usually used in combination.1,14 In refractory cases, adminis-
tration of  L-5-hydroxytryptophan (L-5-HTP), piracetam, lacosamide, 
zonisamide, and agomelatine has been used.15,16,17,18 Deep brain stimula-
tion (DBS) has been attempted in multi-drug-resistant patients, with 
partially positive results upon targeting the globus pallidus internus 
(GPi).19,20,21,22 In refractory cases, sodium oxybate (SBX) has been used 
as well, with good results.
SBX is a sodium salt of  γ-hydroxybutyrate that has been found to be 
effective in ameliorating alcohol-responsive movement disorders. Currently, 
it has been approved for the treatment of  excessive daytime sleepiness and 
cataplexy in narcolepsy in the United States, and also for the treatment of  
alcohol dependency and acute alcohol withdrawal in some European coun-
tries. Promising results have been reported in patients with treatment- 
refractory alcohol-responsive movement disorders, such as myoclonus 
dystonia, essential tremor, spasmodic dysphonia, vocal tremor, and recently 
also for excessive daytime sleepiness in Parkinson’s disease.23,24,25,26,27 The 
most common adverse events described with SBX use are excessive seda-
tion, respiratory impairment, and depression.
The benefit of  alcohol in LAS was first reported in 1992, but few 
cases have been described in the literature.28 Here we report a new 
patient affected with PHM who was successfully treated with SBX. We 
also review our experience and cases reported in the literature compar-
ing their clinical outcome measures. The purpose of  this study is to 
bring together experience with SBX in PHM, as this drug represents a 
potentially important option for patients who are severely affected and 
refractory to treatment with other medications.
Case series
Case 1
A healthy 19-year-old man presented sudden shortness of  breath 
after bilateral spontaneous pneumothorax. On his way to the hospital, 
he suffered a cardiac arrest and received cardiopulmonary resuscitation 
(CPR) for about 6 minutes in the ambulance. He was resuscitated and 
then admitted to the intensive care unit (ICU), where he developed sei-
zures, autonomic storm, and continuous myoclonic jerks. Profound 
myoclonus at rest and with action persisted upon his awakening 
(Video 1, segment 1). Written informed consent was obtained for video 
recording. Brain magnetic resonance imaging (MRI) showed bilateral 
T2/FLAIR hyperintensity of  putamen and caudate, with negative dif-
fusion restriction. EEG showed severe generalized slowing, with no 
events correlating with his jerks. After 4 months, resting and kinetic 
myoclonic jerks were still present despite treatment with valproic acid 
(1,000 mg), levetiracetam (1,000 mg), and zolpidem (5 mg). Previously, 
he tried also lacosamide (300 mg) and clonazepam (4.5 mg). Myoclonus 
was severely debilitating, to the point that he required a PEG tube for 
feeding. Based on the supposition that his myoclonus might be alco-
hol-responsive, he was admitted to the hospital for an observed initia-
tion and titration with sodium oxybate (Xyrem). He was started on 
Xyrem 1 g and then gradually increased up to 1.5, 2, and 2.5 g. He 
showed a profound improvement in myoclonus in dose-dependent man-
ner, experiencing benefit 30–45 minutes after dose administration. At 
2 g, myoclonus at rest disappeared in 40 minutes, and he was able to sit 
calmly in the chair. Action myoclonus was still present, but he was able 
to hold and transfer objects, to brush and comb his hair, and to feed 
himself  (Video 1, segment 2). At present, he continues on Xyrem 2 g 
four times daily. He responds to each dose within 30 minutes, with each 
dose lasting about 3 hours. He is slowly improving. He is now able to 
stand for a few seconds with assistance, and he is no longer PEG fed. 
Video 1. Clinical Presentation of  the Patient Described in the Paper 
before and after Treatment with SBX. The first part of  the video docu-
ments our patient’s baseline examination. There is prominent myoclonus at rest 
and with action. The second part of  the video presents the clinical outcome after 
1 hour of  administration of  SBX 2 g. Myoclonus at rest is abolished, and there is 
significant improvement of  action myoclonus.
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1 19 <1 Bilateral 
PNX
6 min VA (1,000 mg), 
LEV (1,000 mg), 
ZLP (5 mg)
2 g QID 3 hours ↓↓ ↓↓  ↓ ↓  None




3.5 hours ↓↓ ↓↓ ↓ No effect dizziness




NA LEV 2,500 mg, 
CZM 6 mg, PBT 
60 mg, ALPZ 0.5 
mg, rabeprazole 20 
mg, BACL 20 mg, 
VA, TZ, PRM, 
GPT, PX, PIR
2 g TID 3.5–4 
hours




30 4 61 NA NA NA CZM, LEV, ZNS 2 g NA ↓a ↓↓a ↓↓a NA NA
30 5 39 NA NA NA CZM, VA, LEV 2 g NA ↓a ↓↓a ↓↓a  NA NA
30 6 62 NA NA NA CZM, LEV, ZNS, 
VA
2 g NA ↓a ↓↓a ↓↓a  NA NA
30 7 38 NA NA NA CZM, LEV, L-5-
HTP, PBT, PIR, 
TPM, VA
2 g NA ↓a ↓↓a ↓↓a  NA NA
29 8 16 1 Bilateral 
PNX
7 minutes PIR (36 g), 
LEV (4,000 mg), 
CZM (11.25 mg), 
VA (2,200 mg) 
5-HTP (1,200 mg)
2 g every 
4 hours
NA ↓↓ ↓↓ ↓ No effect Somnolence, 
GI distress
Abbreviations: ALPZ, Alprazolam; AOO, age of onset; BACL, baclofen; CZM, clonazepam; GI, gastrointestinal; GPT, gabapentin; HA, headache; 
LEV, levetiracetam; NA, not available; PBT, phenobarbital; PIR, piracetam; PRM, primidone; PX, paroxetine; TPM, topiramate; TZ, tizanidine; 
VA, valproic acid; ZLP, zolpidem; ZNS, zonisamide.
a Results expressed as average of cases reported in the paper.
Subsequently, he has undergone DBS of  the GPi, with continued 
improvement.
Other cases
Published cases of  PHM treated with SBX are summarized in 
Table 1.25,26,29,30 The mean age of  onset of  PHM was 40.1 years (range 
16–62 years). In these patients, the leading event was represented by cardiac 
arrest, bilateral spontaneous pneumothorax, and anesthesia-induced 
hypoxia. In most instances, patients suffered a prolonged anoxic insult, up 
to 7 minutes. The onset of  myoclonus usually occurred within 24 hours 
after the leading event, as soon as sedation was discontinued. Brain imaging 
was available only in two of  the reported cases, showing mild atrophy in one 
patient (case 2), while hyperintensity of  the basal ganglia (caudate, putamen, 
and pallidum) in T1- and T2-weighted images was present in the other 
case, as typically seen in hypoxic damage (case 8).
All patients, except case 4, were treated with levetiracetam, clonaze-
pam, and valproic acid, plus a combination of  other benzodiazepine 
(alprazolam), sedatives (zolpidem), antiepileptic drugs (e.g., phenobarbi-
tal, piracetam, topiramate, gabapentin, zonisamide, and primidone), and 
muscle relaxants (tizanidine and baclofen). Cases 7 and 8 were treated 
Figure 1. Graphic Representation of  the Outcome Measure of  
the UMRS before and after Treatment with Sodium Oxybate 
(SBX).The average of  the scores for the six sections of  the UMRS was cal-
culated from patient data available in the literature. Scores were calculated 
before and after treatment with the most effective dose of  SBX for each 
patient. Pre- and post-treatment average scores are reported next to 
each  vector. Subscore for each patient and dosages of  SBX are reported in 
Table 2.
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also with 5-hydroxytroptophane while in another case (case 3) paroxetine 
was attempted. Despite these various combinations of  treatments, myoc-
lonus remained refractory and severe. In seven out of  eight patients 
(cases 2–7), symptoms were alcohol responsive. The treatment refractory 
nature and alcohol responsivity lead to the decision to try SBX.
In all patients, myoclonus was noted to improve in dose-dependent 
manner. The results were evaluated in the majority of  the cases through 
standardized scales (i.e., Unified Myoclonus Rating Scale – UMRS) and 
review of  videos31 (Figure 1). Stimulus-induced myoclonus significantly 
decreased in all cases, while improvement in resting and action myoclo-
nus varied between patients (Table 2). Negative myoclonus was less 
responsive to treatment, although physiologic confirmation of  this effect 
was lacking. SBX was slowly titrated in all patients, increasing each dose 
by 0.5–1 g every 2 weeks in order to maximize the tolerability of  the 
medication, reduce adverse events, and establish the minimally effective 
dose. The average dose required by this cohort of  patients was 2 g three 
to four times daily, with the effect of  each dose lasting for 3–4 hours on 
average. Latency from the onset of  myoclonus to treatment did not 
seem to affect the efficacy of  the treatment. No serious adverse events 
were reported, while asthma and sedation were reported in few cases 
(cases 2 and 3). All patients and their caregivers were aware of  the kinet-
ics of  the medication.
Table 2. Outcome Measures
Reference
Patient Number in 
the Original Paper
Sodium Oxybate Dosage
0 g 1 g 2 g 2.5 g 3 g 4 g
Scores
Section 1 (Patient Questionnaire)
26 1 33 / 31 / 25 18
25 1 33 / / / 31 /
29 1 60 60 58 48 / /
Section 2 (Myoclonus at Rest)
26 1 21 / 8 / 3 1
25 1 3 3 0 0 3 /
29 1 128 120 41 0 / /
Section 3 (Stimulus Sensitivity)
26 1 12 / 5 / 1 1
25 1 8 3 1 2 3 /
29 1 17 17 15 10 / /
Section 4 (Myoclonus with Action)
26 1 108 / 70 / 64 53
25 1 108 96 64 54 86 /
29 1 112 112 66 40 / /
Section 5 (Functional Tests)
26 1 20 / 10 / 8 7
25 1 20 20 13 12 15 /
29 1 20 20 19 14 / /
Section 6 (Global Disability Score)
26 1 3 / 2 / 2 2
25 1 4 3 3 2 3 /
29 1 4 4 4 2 / /
Note: Scores for the different sections of the Unified Myoclonus Rating Scale (UMRS) that were available in the literature are reported 
in the table. Different doses of SBX were tested in each patient. The scores for the different dosages administered to each patient are 
reported. Section 1 (patient questionnaire): range 0–44; Section 2 (myoclonus at rest): range 0–108; Section 3 (stimulus sensitivity): range 
0–17; Section 4 (myoclonus with action): range 0–160; Section 5 (functional tests): range 0–28; Section 6 (global disability score): range 0–4.
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Discussion
After posthypoxic insult, severe and debilitating myoclonus can be 
present in 30–40% cases and can severely affect the quality of  life of  
those who survive life-threatening cardiopulmonary arrests.29 The 
treatment of  PHM is often challenging. Patients often recover their 
cognitive abilities, and they and their families experience significant 
frustration and anxiety over the unpredictability and empiric nature 
of  available treatments. Patience is required to titrate and adjust 
medication dosing in order to find a combination that will best 
address individual patient’s needs.32 Of  available treatments, antiepi-
leptic drugs, benzodiazepines, L-5-HTP, agomelatine, and GPi DBS 
have been attempted with promising results.32 However, some cases 
of  PHM can be resistant to available combinations of  medications. 
SBX may represent a promising option for these treatment refrac-
tory patients.
SBX is a precursor of  GABA that easily crosses the blood–brain bar-
rier and modulates the GABA-A receptors.33 Our patient experienced 
improvement in resting and stimulus-induced myoclonus, and moderate 
improvement in action myoclonus, allowing him to regain a satisfactory 
degree of  autonomy in many of  his daily activities (such as eating, wash-
ing himself, and manipulating small objects, as well as standing) that 
were completely lost prior to treatment. Other patients reported in the 
literature have experienced similar benefit.25,29,30
We are aware of  the open-label nature of  this experience, with the 
inherent bias for placebo response. Nevertheless, the often-dramatic 
nature of  the response and the clear pharmacokinetics support the 
potential efficacy of  SBX in PHM. In our opinion, SBX should not be 
used as a first-line agent in PHM, as many patients will obtain adequate 
benefit from available medications such as clonazepam, levetiracetam, 
valproic acid, and zonisamide. In patients who do not respond to these 
agents, SBX may be proposed as a possible treatment. In all the cases 
reported in the literature, SBX was initially tested as an add-on treat-
ment. Should SBX be effective, discontinuation or dosage modification 
of  other medications can be considered, especially in case of  side effects. 
However, in the majority of  cases, patients with PHM will remain on 
polytherapy. An observed alcohol challenge can be very helpful in doc-
umenting responsivity, and also convincing the patient’s family and care 
team about the merit of  this approach. However, this is not strictly 
required in order to start the treatment with SBX. Indeed, in severely 
refractory patients with PHM, in the attempt to better treat patients’ 
symptoms it should be worth considering SBX even if  an alcohol 
responsivity has not been clearly documented. Wherever possible, vid-
eotaped evaluations using the UMRS should be performed before and 
1 hour after dose initiation in order to document tolerability and effi-
cacy. Starting with a twice-daily dose regimen is wise, at low dose (1 g 
per dose). In the hospital setting, individual dosing can be increased 
quickly, even daily, by 0.5 g increments. If  the response is robust, and 
tolerability is satisfactory, dosing can be changed to thrice daily. Long-
term use generally is characterized by continuation in prior efficacy and 
tolerability. In patients who are still severely disabled by myoclonus, 
SBX may be used as a bridge to consider more invasive treatments, such 
as deep brain stimulation.
We are aware of  the limitation of  the reported observations given 
the small number of  subjects of  this cohort and the lack of  place-
bo-controlled trials. However, the outcomes of  the reported cases are 
very promising, and they should open the way for further studies 
with larger cohort of  subjects in order to better define the extent of  
the response to SBX in PHM and formulate guidelines.
References
1. Frucht S, Fahn S. The clinical spectrum of  posthypoxic myoclonus. 
Mov Disord 2000;15 Suppl 1:2–7.
2. Lance JW, Adams RD. The syndrome of  intention or action myoclonus as 
a sequel to hypoxic encephalopathy. Brain 1963;86:111–36.
3. Espay AJ, Chen R. Myoclonus. Continuum 2013;19(5 Movement 
Disorders):1264–1286.
4. Hallett M. Physiology of  human posthypoxic myoclonus. Movement Disorders 
2000;15 Suppl 1:8–13.
5. Welsh JP, Placantonakis DG, Warsetsky SI, Marquez RG, Bernstein L, 
Aicher SA. The serotonin hypothesis of  myoclonus from the perspective of  neu-
ronal rhythmicity. Adv Neurol 2002;89:307–329.
6. Matsumoto RR, Truong DD, Nguyen KD, Dang AT, Hoang TT, Vo PQ, 
et al. Involvement of  GABA(A) receptors in myoclonus. Mov Disord 2000;15 
Suppl 1:47–52.
7. Zhang YX, Liu JR, Jiang B, Liu HQ, Ding MP, Song SJ, et al. Lance-Adams 
syndrome: a report of  two cases. J Zhejiang Univ Sci B 2007;8(10):715–720.
8. Park KM, Han YH, Kim TH, Mun CW, Shin KJ, Ha SY, et al. Increased 
functional connectivity between motor and sensory cortex in a patient with 
Lance-Adams syndrome. Clin Neurol Neurosurg 2015;139:241–243.
9. Lee HL, Lee JK. Lance-adams syndrome. Ann Rehabil Med 2011;35(6): 
939–943.
10. Hiramatsu N, Shime N, Kageyama K, Ashida H, Itoi T, Tanaka Y. 
Intention myoclonus in paediatric patients following severe cardiopulmonary 
failure: a report of  three cases. Crit Care Resusc 2002;4(2):104–106.
11. Frucht SJ, Trost M, Ma Y, Eidelberg D. The metabolic topography of  
posthypoxic myoclonus. Neurology 2004;62(10):1879–1881.
12. Gupta HV, Caviness JN. Post-hypoxic Myoclonus: current concepts, neu-
rophysiology, and treatment. Tremor Other Hyperkinet Mov 2016;6:409.
13. Freund B, Sutter R, Kaplan PW. Lance-Adams syndrome in the pretar-
geted temperature management era. Clin EEG Neurosci 2017;48(2):130–138.
14. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy 
study of  levetiracetam in patients with chronic myoclonus. Neurology 2001;57(6): 
1112–1114.
15. Striano P, Manganelli F, Boccella P, Perretti A, Striano S. Levetiracetam 
in patients with cortical myoclonus: a clinical and electrophysiological study. Mov 
Disord 2005;20(12):1610–1614.
16. Polesin A, Stern M. Post-anoxic myoclonus: a case presentation and review 
of  management in the rehabilitation setting. Brain Inj 2006;20(2):213–217.
17. Gonzalez de la Aleja J, Saiz-Diaz RA, De la Pena P. Relief  of  intractable 
posthypoxic myoclonus after administration of  agomelatine. Clin Neuropharmacol 
2012;35(5):258–259.
18. Galldiks N, Timmermann L, Fink GR, Burghaus L. Posthypoxic myoclo-
nus (Lance-Adams syndrome) treated with lacosamide. Clin Neuropharmacol 
2010;33(4):216–217.
Riboldi GM and Frucht SJ Posthypoxic Myoclonus and Sodium Oxybate
Columbia University Libraries
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org 6
19. Yamada K, Sakurama T, Soyama N, Kuratsu J. Gpi pallidal stimulation 
for Lance-Adams syndrome. Neurology 2011;76(14):1270–1272.
20. Ramdhani RA, Frucht SJ, Kopell BH. Improvement of  post-hypoxic 
myoclonus with bilateral pallidal deep brain stimulation: a case report and review 
of  the literature. Tremor Other Hyperkinet Mov 2017;7:461.
21. Kobayashi K, Katayama Y, Otaka T, Obuchi T, Kano T, Nagaoka T, 
et al. Thalamic deep brain stimulation for the treatment of  action myoclonus 
caused by perinatal anoxia. Stereotact Funct Neurosurg 2010;88(4):259–263.
22. Asahi T, Kashiwazaki D, Dougu N, Oyama G, Takashima S, Tanaka K, 
et al. Alleviation of  myoclonus after bilateral pallidal deep brain stimulation for 
Lance-Adams syndrome. J Neurol 2015;262(6):1581–1583.
23. Rumbach AF, Blitzer A, Frucht SJ, Simonyan K. An open-label study of  
sodium oxybate in Spasmodic dysphonia. Laryngoscope 2017;127(6):1402–1407.
24. Priori A, Bertolasi L, Pesenti A, Cappellari A, Barbieri S. gamma-hydroxy-
butyric acid for alcohol-sensitive myoclonus with dystonia. Neurology 2000;54(8):1706.
25. Frucht SJ, Bordelon Y, Houghton WH, Reardan D. A pilot tolerability 
and efficacy trial of  sodium oxybate in ethanol-responsive movement disorders. 
Mov Disord 2005;20(10):1330–1337.
26. Frucht SJ, Bordelon Y, Houghton WH. Marked amelioration of  alco-
hol-responsive posthypoxic myoclonus by gamma-hydroxybutyric acid (Xyrem). 
Mov Disord 2005;20(6):745–751.
27. Buchele F, Hackius M, Schreglmann SR, Omlor W, Werth E, Maric A, 
et al. Sodium Oxybate for excessive daytime sleepiness and sleep disturbance 
in Parkinson disease: a randomized clinical trial. JAMA Neurol 2018;75(1): 
114–118.
28. Genton P, Guerrini R. Effect of  alcohol on action myoclonus in 
Lance-Adams syndrome and progressive myoclonus epilepsy. Mov Disord 
1992;7(1):92.
29. Arpesella R, Dallocchio C, Arbasino C, Imberti R, Martinotti R, 
Frucht SJ. A patient with intractable posthypoxic myoclonus (Lance-Adams 
syndrome) treated with sodium oxybate. Anaesth Intensive Care 2009;37(2): 
314–318.
30. Frucht SJ, Houghton WC, Bordelon Y, Greene PE, Louis ED. A sin-
gle-blind, open-label trial of  sodium oxybate for myoclonus and essential tremor. 
Neurology 2005;65(12):1967–1969.
31. Frucht SJ, Leurgans SE, Hallett M, Fahn S. The Unified Myoclonus 
Rating Scale. Adv Neurol 2002;89:361–376.
32. Levy A, Chen R. Myoclonus: pathophysiology and treatment options. 
Curr Treat Options Neurol 2016;18(5):21.
33. Waszkielewicz A, Bojarski J. Gamma-hydrobutyric acid (GHB) and its 
chemical modifications: a review of  the GHBergic system. Pol J Pharmacol 
2004;56(1):43–49.
